BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HDM1005 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HDM1005\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07502001-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:HDM1005: Phase 1 readout est. (NCT07502001)
DESCRIPTION:HDM1005\, phase 1\, Obesity.\nStudy: Influence of HDM1005 on Ga
 stric Emptying and Pharmacokinetics of Metformin\, Atorvastatin\, Warfarin
 \, and Digoxin\nEstimated primary completion: 1 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07502001
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521631-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:HDM1005: Phase 2 readout est. (NCT07521631)
DESCRIPTION:HDM1005\, phase 2\, Obesity.\nStudy: Efficacy and Safety of HDM
 1005 Compared to Tirzepatide in Obese Adults Without Diabetes\nEstimated p
 rimary completion: 4 February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07521631
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394114-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270828
DTEND;VALUE=DATE:20270829
SUMMARY:HDM1005: Phase 3 readout est. (NCT07394114)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 28 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07394114
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417306-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HDM1005: Phase 3 readout est. (NCT07417306)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With T2DM Not Controlled With Metformin Alone or in Combi
 nation With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor\nEstimated 
 primary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07417306
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787260-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HDM1005: Phase 3 readout est. (NCT07787260)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PA
 P) Therapy\nEstimated primary completion: March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07787260
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794397-196@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:HDM1005: Phase 3 readout est. (NCT07794397)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) T
 herapy\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07794397
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
